| Autor: |
Masanori, Atsukawa, Akihito, Tsubota, Yohei, Koushima, Tadashi, Ikegami, Kouji, Watanabe, Noritomo, Shimada, Shinichi, Sato, Keizo, Kato, Hiroshi, Abe, Tomomi, Okubo, Taeang, Arai, Norio, Itokawa, Chisa, Kondo, Shigeru, Mikami, Toru, Asano, Yoshimichi, Chuganji, Yasushi, Matsuzaki, Katsuhiko, Iwakiri |
| Rok vydání: |
2017 |
| Zdroj: |
Hepatology research : the official journal of the Japan Society of Hepatology. 47(13) |
| ISSN: |
1386-6346 |
| Popis: |
From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety of this combination that have not yet been addressed in patients undergoing dialysis.A retrospective, multicenter study evaluated the outcome of 12-week ombitasvir (non-structural protein [NS]5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir combination therapy for dialysis patients. The primary end-point was sustained virologic response 12 weeks after therapy (SVR12).The subjects were 31 patients with a median age of 64 years (range, 49-85 years), including 10 cirrhotic patients. All of the 31 patients had an estimated glomerular filtration rate level 15 mL/min/1.73 mThe present study suggests that ombitasvir/paritaprevir/ritonavir combination therapy is effective and safe for genotype 1b chronic hepatitis C patients undergoing dialysis due to ESRD. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
